Serum proteomic profiling of patients with compensated advanced chronic liver disease with and without clinically significant portal hypertension
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0301416 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Frane Pastrovic und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hepatology and Clinical Nutrition, Laboratory for Liver Diseases and Portal Hypertension, University Hospital Dubrava…. Hauptthemen laut MEDLINE: Hypertension, Portal, Elasticity Imaging Techniques. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Adris Foundation, Knowledge and Discovery Programme, European Regional Development Fund and the BIMIS - Biomedical Research Center Šalata, University of Zagreb, School of Medicine.
Abstract (Originalsprache)
Introduction
Portal hypertension (PH) drives the progression of liver cirrhosis to decompensation and death. Hepatic venous pressure gradient (HVPG) measurement is the standard of PH quantification, and HVPG≥10 mmHg defines clinically significant PH (CSPH). We performed proteomics-based serum profiling to search for a proteomic signature of CSPH in patients with compensated advanced chronic liver disease (cACLD). Materials and methods Consecutive patients with histologically confirmed cACLD and results of HVPG measurements were prospectively included. Serum samples were pooled according to the presence/absence of CSPH and analysed by liquid chromatography-mass spectrometry. Gene set enrichment analysis was performed, followed by comprehensive literature review for proteins identified with the most striking difference between the groups.
Results
We included 48 patients (30 with, and 18 without CSPH). Protein CD44, involved in the inflammatory response, vascular endothelial growth factor C (VEGF-C) and lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1), both involved in lymphangiogenesis were found solely in the CSPH group. Although identified in both groups, proteins involved in neutrophil extracellular traps (NET) formation, as well as tenascin C, autotaxin and nephronectin which mediate vascular contractility and lymphangiogenesis were more abundant in CSPH. Discussion and conclusion We propose that altered inflammatory response, including NET formation, vascular contractility and formation of new lymph vessels are key steps in PH development. Proteins such as CD44, VEGF-C, LYVE-1, tenascin C, Plasminogen activator inhibitor 1, Nephronectin, Bactericidal permeability-increasing protein, Autotaxin, Myeloperoxidase and a disintegrin and metalloproteinase with thrombospondin motifs-like protein 4 might be considered for further validation as potential therapeutic targets and candidate biomarkers of CSPH in cACLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Hepatology and Clinical Nutrition, Laboratory for Liver Diseases and Portal Hypertension, University Hospital Dubrava, Zagreb, Croatia.
- Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia.
- Department of Proteomics, Center for Translational and Clinical Research, University of Zagreb School of Medicine, Zagreb, Croatia.
- University of Zagreb, School of Medicine, Zagreb, Croatia.
- Biomedical Research Center Salata, University of Zagreb, School of Medicine, Zagreb, Croatia.
- Department of Clinical Immunology, Allergology and Rheumatology, University Hospital Dubrava, Zagreb, Croatia.
ORCID-Profile: Frane Pastrovic, Ivica Grgurevic, Marko Zarak
Förderung
- Adris Foundation, Knowledge and Discovery Programme
- European Regional Development Fund and the BIMIS - Biomedical Research Center Šalata, University of Zagreb, School of Medicine
Zitieren
APA
Pastrovic, F., Novak, R., Grgurevic, I., Hrkac, S., Salai, G., Zarak, M., & Grgurevic, L. (2024). Serum proteomic profiling of patients with compensated advanced chronic liver disease with and without clinically significant portal hypertension. PLOS ONE. https://doi.org/10.1371/journal.pone.0301416
Vancouver
Pastrovic F, Novak R, Grgurevic I, Hrkac S, Salai G, Zarak M, et al. Serum proteomic profiling of patients with compensated advanced chronic liver disease with and without clinically significant portal hypertension. PLOS ONE. 2024. doi:10.1371/journal.pone.0301416
BibTeX
@article{Pastrovic2024,
author = {Pastrovic, Frane and Novak, Rudjer and Grgurevic, Ivica and Hrkac, Stela and Salai, Grgur and Zarak, Marko and Grgurevic, Lovorka},
title = {Serum proteomic profiling of patients with compensated advanced chronic liver disease with and without clinically significant portal hypertension},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0301416}
}
EUVIMED